Search Results

Pictured: Woman scratching her wrist/iStock, Image

Business

Medicxi Combines Six Portfolio Companies with $100M to Launch Alys Pharma

Merging six of its portfolio biotechs, Medicxi on Monday unveiled Alys Pharmaceuticals, an immuno-dermatology focused company seeking to deliver up to 10 proof-of-concept readouts by the end of 2026.

February 12, 2024

·

2 min read

·

Tristan Manalac

D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline

D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm.

April 8, 2024

·

2 min read

Deals

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo.

October 3, 2022

·

7 min read

Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund.

July 18, 2019

·

3 min read

Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi

Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of €18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi.

January 9, 2020

·

3 min read

Pictured: Financing concept/Getty Images

Business

Vaderis Forms to Tackle Vascular Malformations with Novartis Vet at the Helm

With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.

August 22, 2022

·

2 min read

·

Alex Keown

BioCapital

Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders

Rivus Pharmaceuticals Inc. today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital.

September 22, 2022

·

4 min read

Press Releases

Levicept to Present Phase II Data at ACR Convergence 2024

October 28, 2024

·

2 min read

Press Releases

Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist

November 12, 2024

·

4 min read

Press Releases

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, for Treatment of Patients with Moderate to Severe Osteoarthritis at ACR Convergence 2024

November 14, 2024

·

3 min read